All Articles
Anticipated launches and uptake of biosimilars are predicted to increase spending to $129 billion and savings by $180 billion over the next 5 years, according to a report by IQVIA. Read More ›
Results from a recent study by Krupal B. Patel, MD, MSc, FRCSC, Surgeon, Department of Head and Neck–Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, and colleagues indicate that the adoption of telehealth services during the pandemic saved patients with cancer both time and travel costs, reducing the cost burden associated with their care. Read More ›
Young women with early-stage, hormone receptor (HR)-positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial. Read More ›
By Luke Auburn
In a new study published in the Journal of Managed Care & Specialty Pharmacy, Teresa Gibson, PhD, Professor of Practice, School of Mathematical Sciences, RIT, showed that an individual’s previous adherence behavior is an important predictor of future adherence. Read More ›
President Biden announced that the public health emergency (PHE) will expire on May 11, 2023. Providers need to review the impact of these upcoming changes, in addition to any others that bear weight on the financial stability of their practices or the ability of patients to access the care they need. Read More ›
On January 27, 2023, the FDA approved elacestrant (Orserdu; Stemline Therapeutics), an estrogen receptor (ER) antagonist, for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative advanced or metastatic breast cancer and an ESR1 mutation whose disease progressed after ≥1 line of endocrine therapy. Read More ›
On January 27, 2023, the FDA accelerated the approval of pirtobrutinib (Jaypirca; Eli Lilly) for the treatment of patients with relapsed or refractory mantle-cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. The FDA granted this indication an orphan drug designation. Read More ›
On December 22, 2022, the FDA granted accelerated approval to mosunetuzumab-axgb (Lunsumio; Genentech), a bispecific CD20-directed CD3 T-cell engager, for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication breakthrough therapy and orphan drug designations. Read More ›
On December 16, 2022, the FDA granted approval to nadofaragene firadenovec-vncg (Adstiladrin; Ferring Pharmaceuticals), a nonreplicating adenoviral vector–based gene therapy, for adults with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non–muscle-invasive bladder cancer (NMIBC) and carcinoma in situ, with or without papillary tumors. The FDA granted this indication breakthrough therapy and orphan drug designations. Read More ›
On December 12, 2022, the FDA accelerated the approval of adagrasib (Krazati; Mirati Therapeutics), a RAS GTPase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and KRASG12C mutation (as determined by an FDA-approved test) who have received at least 1 systemic therapy. Adagrasib received breakthrough therapy and orphan drug designations for this indication. Read More ›